Compare MI & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MI | APLT |
|---|---|---|
| Founded | 2009 | 2016 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.5M | 38.1M |
| IPO Year | N/A | 2019 |
| Metric | MI | APLT |
|---|---|---|
| Price | $4.30 | $0.22 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $1.25 |
| AVG Volume (30 Days) | 6.3K | ★ 27.5M |
| Earning Date | 01-01-0001 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $662,718.00 | ★ $1,000,000.00 |
| Revenue This Year | N/A | $124.18 |
| Revenue Next Year | N/A | $66.67 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.57 | $0.20 |
| 52 Week High | $8.61 | $1.50 |
| Indicator | MI | APLT |
|---|---|---|
| Relative Strength Index (RSI) | 65.68 | 30.66 |
| Support Level | $3.87 | $0.21 |
| Resistance Level | $4.10 | $0.26 |
| Average True Range (ATR) | 0.20 | 0.03 |
| MACD | 0.09 | 0.02 |
| Stochastic Oscillator | 98.70 | 16.86 |
NFT Ltd operates an online electronic platform for offering and trading artwork. Through its platform, the company allows artists/art dealers/owners to access a much bigger art trading market where artists can engage with a wide range of investors. Its platform also invests in high-end artwork accessible to ordinary people without financial resources. The company's trading platforms comprise the sale of calligraphies and paintings, jewelry, and precious stones. It generates revenue in the form of services in connection with the offering and trading of artwork on its system, consisting of listing fees, trading commissions, and management fees.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.